

#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jean Mesens *et al.*

Appl. No. 08/808,261

Filed: February 28, 1997

For: **Microencapsulated 3-Piperidinyl-
Substituted 1,2-Benzisoxazoles
and 1,2-Benzisothiazoles**

Art Unit: 1205

Examiner: To be assigned

Atty. Docket: 00166.0051.0002 (New)
1611.0510002 (Old)

**Revocation of Prior Power of Attorney and Appointment of New
Attorneys of Record**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The above-captioned application is a continuation of application number 08/154,403, filed November 19, 1993. As such, Alkermes Controlled Therapeutics, Inc. II and Janssen Pharmaceutica are the assignees of the entire right, title and interest in the above-captioned application by virtue of the assignments recorded on May 6, 1996 at reel 7925, frame 0165 and on March 15, 1994 at reel 6948, frame 0281, respectively. The undersigned, having express authority to represent Alkermes Controlled Therapeutics, Inc. II and Janssen Pharmaceutica, hereby revokes all powers of attorney heretofore given in the above-captioned application and appoints as his attorneys Jeffrey I. Auerbach, Reg. No. 32,680; Melvin L. Barnes, Jr., Reg. No. 38,375; Michael J. Bell, Reg. No. 39,604; Mark R. Buscher, Reg. No.

35,006; Celine T. Callahan, Reg. No. 34,301; Cono A. Carrano, Reg. No. 39,623; James F. Davis, Reg. No. 21,072; Thomas M. Dunham, Reg. No. 39,965; Joel M. Freed, Reg. No. 25,101; Alan M. Grimaldi, Reg. No. 26,599; Alexander J. Hadjis, Reg. No. 36,540; Albert P. Halluin, Reg. No. 25,227; Michael N. Haynes, Reg. No. 40,014; Richard H. Kjeldgaard, Reg. No. 30,186; Joseph P. Lavelle, Reg. No. 31,036; David R. Marsh, Reg. No. 41,408; Kevin W. McCabe, Reg. No. 41,182; Joseph A. Micallef, Reg. No. 39,772; Anthony D. Miller, Reg. No. 34,394; Karen L. Nicastro, Reg. No. 35,968; Russell O. Paige, Reg. No. P40,758; Stephen J. Pentlicki, Reg. No. 40,125; Andrea G. Reister, Reg. No. 36,253; Stephen J. Rosenman, Reg. No. 29,209; David P. Ruschke, Reg. No. 40,151; Timothy L. Scott, Reg. No. 37,931; Anthony W. Shaw, Reg. No. 30,104; Serge Sira, Reg. No. 39,445; J. David Smith, Reg. No. 39,839; and Michael J. Songer, Reg. No. 39,841, with full power of substitution, association, and revocation, to prosecute said application and to transact all business in the United States Patent and Trademark Office connected therewith.

The undersigned hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

HOWREY & SIMON
Box No. 34
1299 Pennsylvania Avenue, N.W.
Washington, DC 20004-2402

Direct Phone Calls to Andrea G. Reister, Esq. at (202) 783-0800.

On behalf of Alkermes Controlled Therapeutics, Inc. II:

FOR: ALKERMES CONTROLLED THERAPEUTICS, INC. II

SIGNATURE: _____

BY: Michael Landine

TITLE: Vice-President

DATE: _____

On behalf of Janssen Pharmaceutica

FOR: JANSSEN PHARMACEUTICA

SIGNATURE: ✓ Wante

BY: Dirk Wante

TITLE: ✓ Head Patent Department

DATE: ✓ Sep. 1, 1997

Certificate Under 37 C.F.R. § 3.73(b) For Multiple Assignees

Applicants: Jean Mesens; Michael E. Rickey; and Thomas J. Atkins

Application No: 08/808,261 Filed: February 28, 1997

For: Microencapsulated 3-Peperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles

Alkermes Controlled Therapeutics, Inc. II, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

Janssen Pharmaceutica, a Belgian Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that they are the assignees of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An Assignment from inventor Jean Mesens of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 6948, Frame 282, or for which a copy thereof is attached.

[or]

B. ☒ A chain of title from the inventor(s) of the patent application identified above to the current assignee as shown below:

1. From: Inv. Michael E. Rickey & Thomas J. Atkins To: Medisorb Tehcnologies International L.P.
The document was recorded in the Patent and Trademark Office at
Reel 6948, Frame 284, or for which a copy thereof is attached.

2. From: Medisorb Technologies International L.P. To: Alkermes Controlled Therapeutics, Inc. II
The document was recorded in the Patent and Trademark Office at
Reel 7925, Frame 0165, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

First Assignee

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee **Alkermes Controlled Therapeutics, Inc. II**.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

Name: Michael Landine

Title: Vice-President

Signature: _____

Second Assignee

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee **Janssen Pharmaceutica**.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

✓ Date: Sept. 1, 1997

Name: Dirk Wante

✓ Title: Head Patent Department

✓ Signature: Wante's